Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

12:20
09/23/18
09/23
12:20
09/23/18
12:20

Boston Scientific announced positive 12-month data from IMPERIAL trial

Boston Scientific announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery. The IMPERIAL trial evaluated the Eluvia Drug-Eluting Vascular Stent System versus the Zilver PTX Drug-Eluting Peripheral Stent in patients with symptomatic peripheral artery disease. PAD occurs when fatty or calcified atherosclerotic material, called plaque, builds up on the walls of the arteries of the legs, restricting blood flow and causing pain, swelling, ulceration and in some cases, the need for amputation of the affected limb. Stents are commonly used to restore and maintain blood flow, reducing symptoms and improving quality of life. In the IMPERIAL trial, the Eluvia stent, which utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel, exhibited superior rates of primary patency, a measure of the target vessel remaining unobstructed at 12 months, and thus able to provide sufficient blood flow to the lower limbs.1 Patients in the Eluvia arm of the study also experienced higher rates of freedom from target lesion revascularization, thus reducing their need for repeat procedures at one year, when compared to those treated with the drug-coated Zilver PTX.

  • 09

    Oct

BSX Boston Scientific
$37.76

-0.07 (-0.19%)

09/04/18
JEFF
09/04/18
UPGRADE
Target $42
JEFF
Buy
Jefferies upgrades Boston Scientific to Buy after TAVR doctor survey
Jefferies analyst Raj Denhoy upgraded Boston Scientific (BSX) to Buy from Hold and raised his price target for the shares to $42 from $34. He upgraded the shares after surveying 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market, Denhoy tells investors in a research note. He notes that by 2022, the U.S. TAVR market is expected to be $3.1B and the global market $6.5B. Boston Scientific's revenue growth can be sustained at 7% through at least 2022, Denhoy writes. That level of growth keeps Boston Scientific at the upper end of medtech growth and supports a positive view on the stock, the analyst adds.
09/04/18
09/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Strong Buy from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he believes investors are underappreciating UPS' long-term Domestic EBIT and 2021 free cash flow outlook, which could be greater than $8B. 2. Qualcomm (QCOM) upgraded to Outperform from Neutral at Macquarie with analyst Srini Pajjuri saying he believes risk/reward is attractive and sees multiple catalysts ahead including a final settlement with Huawei in the near future, increasing probability of an Apple (AAPL) settlement, and a 5G cycle that is not fully reflected in consensus estimates. 3. Albemarle (ALB) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. 4. Univar (UNVR) upgraded to Buy from Hold at Berenberg with analyst Thomas Burlton saying the company is improving its conversion margin and EBITDA growth while its cash generation is also getting better. 5. Boston Scientific (BSX) upgraded to Buy from Hold at Jefferies with analyst Raj Denhoy citing a survey of 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/18
ARGS
09/05/18
NO CHANGE
Target $41
ARGS
Buy
Boston Scientific price target raised to $41 from $36 at Argus
Argus analyst Jasper Hellweg raised his price target on Boston Scientific to $41 and kept his Buy rating, saying the company's outperformance over the past 3 months has been driven by its new product and acquisition news. Hellweg further cites the company's Q2 results showing organic sales growth up in all 3 of its sectors and across all regions. The analyst also notes that the stock price is trading in a bullish pattern of higher lows and highs going back to 2012 and believes that Boston Scientific is deserving of its premium valuation based on its growth outlook and profitability profile.
09/10/18
NEED
09/10/18
NO CHANGE
Target $43
NEED
Strong Buy
Boston Scientific price target raised to $43 from $39 at Needham
Needham analyst Mike Matson raised his price target on Boston Scientific to $43 and kept his Strong Buy rating. The analyst cites the company's latest $500M bid Augmenix, whose SpaceOAR reduces side effects associated with prostate radiotherapy. While the company expects "immaterial" earnings impact from the deal through 2019, Matson believes that it will strengthen its Urology & Pelvic Health business longer term, with added potential "revenue synergies given BSX's NxThera acquisition and legacy GreenLight XPS system".

TODAY'S FREE FLY STORIES

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:11
10/16/18
10/16
06:11
10/16/18
06:11
Hot Stocks
BlackRock reports Q3 AUM $6.4T, up 8% y/y »

Including $28B of net AUM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

ADBE

Adobe

$238.05

-10.84 (-4.36%)

06:11
10/16/18
10/16
06:11
10/16/18
06:11
Recommendations
Adobe analyst commentary  »

Adobe remains a top pick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

, SNY

Sanofi

$43.45

0.56 (1.31%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Periodicals
Pharma pushes back against required listing of drug prices in TV ads, WSJ says »

The pharmaceutical…

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

SNY

Sanofi

$43.45

0.56 (1.31%)

RHHBY

Roche

$0.00

(0.00%)

AZN

AstraZeneca

$37.46

0.31 (0.83%)

PFE

Pfizer

$43.11

-0.67 (-1.53%)

LLY

Eli Lilly

$110.69

0.2 (0.18%)

MRK

Merck

$69.46

-0.31 (-0.44%)

GSK

GlaxoSmithKline

$38.87

0.56 (1.46%)

NVS

Novartis

$83.14

0.37 (0.45%)

BMY

Bristol-Myers

$57.59

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 24

    Dec

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 28

    Apr

AMZN

Amazon.com

$1,760.99

-27.64 (-1.55%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Periodicals
Amazon's announcement of HQ2 'imminent,' Recode reports »

Amazon's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

, MNKD

MannKind

$1.66

0.06 (3.75%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Hot Stocks
United Therapeutics, MannKind announce closing of license agreement »

United Therapeutics…

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

MNKD

MannKind

$1.66

0.06 (3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:09
10/16/18
10/16
06:09
10/16/18
06:09
Earnings
BlackRock reports Q3 adjusted EPS $7.52, consensus $6.84 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

06:08
10/16/18
10/16
06:08
10/16/18
06:08
Hot Stocks
J.B. Hunt CFO says Oct peak season freight should be 'very normal', Dec 'strong' »

In its conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

LN

Line Corp.

$35.10

-0.81 (-2.26%)

06:07
10/16/18
10/16
06:07
10/16/18
06:07
Upgrade
Line Corp. rating change  »

Line Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$11.42

0.03 (0.26%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Upgrade
Noodles & Company rating change  »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Hot Stocks
Volkswagen reports negative special items from Audi administrative order »

Volkswagen (VLKAY)…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$121.06

-1.61 (-1.31%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Recommendations
Wayfair analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 03

    Mar

GOV

Government Properties

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Upgrade
Government Properties rating change  »

Government Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SNN

Smith & Nephew

$34.14

-0.42 (-1.22%)

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Downgrade
Smith & Nephew rating change  »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNKD

MannKind

$1.66

0.06 (3.75%)

, UTHR

United Therapeutics

$123.41

0.26 (0.21%)

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Hot Stocks
MannKind and United Therapeutics close pending worldwide agreement »

United Therapeutics…

MNKD

MannKind

$1.66

0.06 (3.75%)

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$18.73

-0.08 (-0.43%)

06:03
10/16/18
10/16
06:03
10/16/18
06:03
Downgrade
Amneal Pharmaceuticals rating change  »

Amneal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 28

    Feb

CBRL

Cracker Barrel

$153.14

2.89 (1.92%)

06:02
10/16/18
10/16
06:02
10/16/18
06:02
Upgrade
Cracker Barrel rating change  »

Cracker Barrel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$14.29

0.18 (1.28%)

06:02
10/16/18
10/16
06:02
10/16/18
06:02
Hot Stocks
Emerald Expositions Events acquires Boutique Design New York »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

JHX

James Hardie

$13.63

0.3 (2.25%)

06:02
10/16/18
10/16
06:02
10/16/18
06:02
Upgrade
James Hardie rating change  »

James Hardie upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUDVF

Audi AG

$0.00

(0.00%)

, VLKAY

Volkswagen

$0.00

(0.00%)

06:02
10/16/18
10/16
06:02
10/16/18
06:02
Hot Stocks
Audi AG fined EUR800M by German prosecutors for diesel violations »

The Munich II public…

AUDVF

Audi AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$93.85

-0.93 (-0.98%)

, AAP

Advance Auto Parts

$166.98

1.86 (1.13%)

06:01
10/16/18
10/16
06:01
10/16/18
06:01
Hot Stocks
Walmart, Advance Auto Parts to launch automotive specialty store on Walmart.com »

Walmart.com (WMT) and…

WMT

Walmart

$93.85

-0.93 (-0.98%)

AAP

Advance Auto Parts

$166.98

1.86 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

  • 15

    Nov

UNH

UnitedHealth

$259.80

0.36 (0.14%)

06:00
10/16/18
10/16
06:00
10/16/18
06:00
Earnings
UnitedHealth raises FY18 adj. EPS view to approaching $12.80 from $12.50-$12.75 

Consensus $12.70.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

UNH

UnitedHealth

$259.80

0.36 (0.14%)

05:58
10/16/18
10/16
05:58
10/16/18
05:58
Hot Stocks
UnitedHealth reports Q3 adj. EPS $3.41, consensus $3.29 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HSBC

HSBC

$41.81

-0.195 (-0.46%)

05:53
10/16/18
10/16
05:53
10/16/18
05:53
Periodicals
HSBC CEO pulls out of Saudi investment conference, Reuters reports »

HSBC CEO John Flint will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KIGRY

Kion Group

$0.00

(0.00%)

05:52
10/16/18
10/16
05:52
10/16/18
05:52
Upgrade
Kion Group rating change  »

Kion Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

$1.47

(0.00%)

05:52
10/16/18
10/16
05:52
10/16/18
05:52
Hot Stocks
Applied DNA Sciences subsidiary LineaRx licenses CAR T candidate »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.